Next, USP17 depletion blocks the proliferation of NSCLC cells regardless of the EGFR mutational status, indicating that USP17 inhibition could represent an opportunity to target the tumors of a large proportion of NSCLC patients. This evidence concerns the gene USP17L2 and non-small cell lung carcinoma.